HAZLET, N.J. - s4story -- In this symposium, HF nurses will be provided with education, through lecture and "real-world" case discussion, that will enable them to 1) use potassium binders effectively and safely with fundamental knowledge about their profiles and clinical trial evidence, and 2) communicate key information to patients about the reasons for initiating potassium binders, and using them long-term with RAAS is to reduce their risk of major adverse outcomes.

Click here for more information

CHAIR

Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC
Associate Chief Nursing Officer--Research and Innovation

More on S For Story

• With a Dream and a Team, Monalisa Okojie Is Empowering the Next Generation Through EXPOSE NGO
• New Eco-Thriller Blue Planet – Red Tide Rises Amid UAP/UFO Disclosure Headlines
• American Properties Realty, Inc. Celebrates 2026 FAME Awards - Community of the Year - Heritage at South Brunswick
• Mel Blackwell to Keynote 2026 NSSF Marketing and Leadership Summit
• SmartCone and Samsung Launch RoadDefender™ to Enhance Real-Time Safety for Roadside Workers

Clinical Nurse Specialist--Kaufman Center for Heart Failure
Cleveland Clinic
Cleveland, Ohio

FACULTY

Stephanie Barnes, DNP, AGNP-C, CHFN
Clinical Director for Advanced Heart Failure
Duke University Health System
Durham, North Carolina

Stephen Greene, MD
Associate Professor of Medicine
Duke University School of Medicine
Duke Clinical Research Institute
Durham, North Carolina

Educational Objectives

• Recognize the relationship of hyperkalemia (or fear of hyperkalemia) and underuse and underdosing of RAASis in HF
• Explain the relationship between down-titration or discontinuation of RAASis and clinical outcomes
• Explain the key characteristics of, and clinical evidence with novel potassium binders
• Identify HF patients who would benefit from novel potassium binders for the treatment of hyperkalemia

Target Audience

More on S For Story

• The Personal Development Industry Has a Blind Spot Says Global Personal Success Guru Omar L. Harris
• Kevin "Mr. Wonderful" O'Leary Begins New Universal Coin & Bullion Promotion of Gold and Silver
• Flamingo Compliance Launches Schengen Area Trip Planning Tools as New Digital Border Controls Take Effect
• HHS Announces Major Push to Address Psychiatric Drug Risks: CCHR Applauds Focus on Informed Consent and Safe Tapering
• PhaseZero Launches Eight AI Agents for Manufacturers and Distributors - Connecting Sales, Support, and Operations Teams Across Full Commerce Journey

This educational activity is intended for Heart Failure Nurses.

Educational Grant
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Accreditation and Credit Designation Statements
This activity is provided by the American Association of Heart Failure Nurses (AAHFN). The American Association of Heart Failure Nurses (AAHFN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.
Attendees may earn continuing education credits (CEC) by attending the meeting and completing the evaluation for the Annual Meeting sessions. Disclaimer: Learners are advised that accredited status does not imply endorsement by the provider, additional provider, or ANCC of any commercial products displayed in conjunction with an activity. Accreditation Provider Number: ANCC Provider Number: P0398.